Abstract. Epigallocatechin gallate (EGCG), one of the major catechins found in green tea, was suggested to play a role as a chemopreventive agent in various human cancer models. In this study, we reported that EGCG has a profound anti-tumor effect on human tongue carcinoma cells by directly regulating glycolysis. EGCG dose-dependently inhibited anchorage-independent growth and short-term EGCG exposure substantially decreased EGF-induced EGF receptor (EGFR), Akt and ERK1/2 activation, as well as the down-regulation of hexokinase 2 (HK2). Furthermore, inhibition of EGCG-mediated HK2 expression was involved in Akt, but not in ERK1/2 signaling pathway suppression. Overexpression of constitutively activated Akt1 rescued inhibition of EGCG-induced glycolysis. Moreover, EGCG inhibited HK2 expression on mitochondrial outer membrane and induced apoptosis. In summary, the results suggested that EGCG or a related analogue, may have a role in the management of human tongue carcinoma.

Introduction
Epidemiologic studies indicate that green tea consumption decreases cancer risk (1-3). Different tea preparations contain varying amounts of polyphenols and epigallocatechin gallate (EGCG) is the most abundant, best-studied and possibly most potent polyphenol against cancer found in green tea (4-6). EGCG reportedly exerts cancer preventive activity at a variety of organ sites, including oral cavity, esophagus, stomach, colon, skin, lung, pancreas and mammary gland (5,7-10). Previous studies suggested that EGCG affects different signal transduction pathways, including inhibition of various protein kinases (11,12), suppression of the activation of transcription factors such as AP-1 (13,14) and NF-κB (15,16), blockade of growth factor receptor-mediated pathways, and induction of cell-cycle arrest or apoptosis (16,17). EGCG was also found to inhibit cell transformation (18), and repress angiogenesis in various cancer models (8,19,20). However, the mechanisms explaining the cancer preventive activity of EGCG remain to be elucidated.

Carcinoma of the oral tongue is the most common cancer in the oral cavity (21). The cause and incidence of tongue carcinoma are associated with different factors, such as genetic (mutations in DNA oncogenes and/or tumor-suppressor genes) and environmental (chemical, physical, smoke and alcohol) (21-23). Oral tongue carcinoma has a high propensity of lymph-node metastasis, even in early local diseases. The incidence of occult nodal metastasis is reportedly 30-40% (24-26). Treatment of tongue carcinoma and conservation of important functions such as language articulation, swallowing and respiration remain a challenge. The overall 5-year disease-free survival rate of tongue carcinoma has not changed substantially over the past decades and has been estimated to be ~50% (26,27). A major challenge in treating tongue carcinoma is to identify novel therapeutic targets or develop new anticancer agents that can complement current surgical treatment.

In general, even in the presence of oxygen, most tumor cells are predisposed to consume glucose through the glycolytic pathway as their major energy source to rapidly generate ATP and biosynthetic intermediates to sustain unlimited growth (28). This phenomenon, which is defined as the Warburg effect, has been consistently observed in most types of cancer, and is considered to be an emerging hallmark of cancer (29). The canonical oncogenic signaling pathways and transcription factors, including PI3-K/Akt, c-Myc and hypoxia-inducible factor 1 (HIF1), are involved in...
the regulation of numerous genes that are responsible for the metabolic difference in the solid tumor, such as hexokinase 2 (HK2), a rate-limiting enzyme of glycolysis, is upregulated in a number of cancers. HK2 overexpression is associated with greater glucose consumption and increased macromolecular biosynthesis. HK2 now has been recognized as a therapeutic target in various types of cancer (33-35).

In the present study, we first reported that HK2 is a key modulator of EGCG-induced glycolysis suppression in human tongue carcinoma cells. We evaluated its underlying mechanism of action and demonstrated that the Akt signaling pathway is involved. The findings suggest that targeting metabolic enzymes may be a novel preventive and therapeutic target in this type of tumor.

Materials and methods

Cell culture and transfection. The Tca8113 and TSCCa human tongue squamous cell carcinoma cell lines were purchased from the China Center for Type Culture Collection (Wuhan University) and cultured with Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% antibiotics. For transfection experiments, the Lipofectamine™ 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) was used according to the manufacturer's instructions.

Reagents and antibodies. EGCG was obtained from Sigma (St. Louis, MO, USA), and Myr-Akt1 was purchased from Addgene (Cambridge, MA, USA). Wortmannin, PD98059, anti-EGFR (Tyr1068), anti-Akt (pan), anti-p-Akt (S473), anti-ERK1/2, anti-p-ERK1/2 (Thr202/Tyr204), anti-HK2, anti-cleaved-PARP, anti-caspase3 and anti-α-tubulin antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Anti-β-actin, anti-rabbit IgG-HRP and anti-mouse IgG-HRP were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-VDAC was purchased from Abcam (Cambridge, UK).

Measurement of glucose uptake and lactate production. Cells (5x10⁵) were seeded in 6-well plates. After incubation for 4 h, the culture medium was discarded and the cells were incubated in fresh medium for another 8 h. Glucose and lactate levels were measured using the Automatic biochemical analyzer (Au680; Beckman Coulter International, Brea, CA, USA). Western blotting. Cells were harvested by trypsinization and pelleted by centrifugation. Cell pellets were lysed in Nonidet P-40 cell lysis buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40 and protease inhibitor mixture). Protein concentrations were determined using the Bradford assay (Bio-Rad, Hercules, CA, USA). Proteins were separated by SDS-PAGE and electrically transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA). After blocking in 5% non-fat dry milk in TBS, the membranes were hybridized to specific primary antibodies overnight at 4°C, washed three times with TBS Tween-20, and then incubated with secondary antibodies conjugated with horseradish peroxidase for 1 h at room temperature. The membranes were then washed three times in TBS Tween-20 at room temperature. The protein bands were visualized using ECL chemiluminescence reagents (Pierce Chemical Co., Rockford, IL, USA) according to the manufacturer's instructions.

Isolation of mitochondrial fractions. Following EGCG treatments, ~5x10⁶ cells from a 10-cm plate were harvested by trypsinization and centrifuged at 800 rpm for 5 min at 4°C. The cell pellets were washed once with ice-cold PBS and then resuspended in three volumes of isolation buffer (20 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl₂, 1 mM sodium EDTA, 1 mM dithiothreitol, 10 mM phenylmethylsulfonyl fluoride, 10 mM leupeptin and 10 mM aprotinin) in 250 mM sucrose. After chilling on ice for 3 min, the cells were disrupted by 60 strokes of a glass homogenizer. The homogenate was centrifuged once at 2,000 rpm at 4°C for 10 min to remove unbroken cells and nuclei. The mitochondria-enriched fraction (supernatant) was then pelleted by centrifugation at 13,000 rpm for 30 min. The pellets were lysed in RIPA buffer [10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl], and analyzed by western blotting.

Soft agar colony formation assay. To assess the anchorage-independent growth, tongue carcinoma cells were suspended (8x10³ cells/ml) in 1 ml of non-agar medium (DMEM containing 10% FBS, 1% antibiotics) and different concentrations of EGCG (0, 20, 40 and 80 µM/l) overlaid in 6-well plates containing a 0.6% agar base. The cultures were maintained in a 37°C, 5% CO₂ incubator for 1-2 weeks, and then colonies were counted under a microscope using the Image-Pro Plus software program (Media Cybernetics, Silver Spring, MD, USA).

Statistical analysis. Statistical analyses were performed using the SPSS software (version 13.0). The experiments were performed in triplicate. Quantitative data are presented as means ± standard deviation. Significant differences between two groups were assessed by a two-tailed Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

EGCG inhibits the anchorage-independent growth of human tongue carcinoma cells. Anchorage-independent growth is one of the malignant phenotypes of tumor cells and is considered to be one of the most accurate and stringent in vitro assays for detecting the malignant transformation of cells. Therefore, we first investigated the effect of EGCG on the anchorage-independent growth of human tongue carcinoma cells. Our results demonstrated that although EGCG had little effect on colony formation at 20 µM, the inhibition rate reached >60% after Tca8113 cells exposure to EGCG at the concentration of 40 µM. More importantly, 80 µM of EGCG almost blocked the colony growth in soft agar (Fig. 1A). We also found that EGCG...
had a similar effect on the suppression of the anchorage-independent growth of TSCCa cells in soft agar (Fig. 1B). These data indicated that EGCG inhibits anchorage-independent growth of human tongue carcinoma cells in a dose-dependent manner.

**EGCG downregulates HK2 expression and decreases human tongue carcinoma cell glycolysis.** Elevated glycolysis is considered to be an emerging hallmark of human cancer. HK2, a rate-limiting enzyme of glycolysis, is upregulated in various cancers (31). Thus, in the present study, we investigated whether EGCG-mediated antitumor activity is associated with tongue carcinoma cell glycometabolism. Immunoblot analysis indicated that the HK2 protein level decreased in response to EGCG treatment in Tca8113 cells (Fig. 2A, left) and a similar result was also observed in TSCCa cells (Fig. 2B, left). To assess the effect of EGCG on glycolysis, we examined the level of glucose consumption and lactate production in the two...
human tongue carcinoma cells. Consistent with the results of the immunoblot analysis, EGCG dose-dependently inhibited the consumption of glucose (Fig. 2A and B, middle) and production of lactate (Fig. 2A and B, right) in the Tca8113 and TSCCa cells. These results suggested that EGCG-mediated tumor suppression is partially dependent on glycolysis inhibition, and HK2 is involved in this process.

**EGCG decreases HK2 expression by downregulating the EGFR-Akt signaling pathway.** Findings of recent studies demonstrated that the Akt signaling pathway is a hub in the regulation of cancer metabolism (36,37). As an Akt upstream receptor tyrosine kinase, the oncoprotein EGFR is always overexpressed in human tongue carcinoma (38). The results showed that EGCG strongly inhibited EGFR-induced EGFR activation and EGCG also significantly inhibited the phosphorylation of EGFR downstream kinases Akt and ERK1/2. Furthermore, we found that the protein levels of HK2 were inhibited following EGCG treatment (Fig. 3A). To determine the connection between ERKs/Akt and HK2 suppression in the presence of EGCG, we used PD98059, a specific inhibitor of the ERKs pathway, to treat Tca8113 and TSCCa cells and examined whether HK2 expression would be affected by the inhibition of the ERKs signaling pathway in these cells. Results indicated that treatment with PD98059 markedly decreased the phosphorylation level of ERKs, however, there was no obvious effect on the expression of HK2 (Fig. 3B). By contrast, wortmannin, a specific inhibitor of the Akt pathway, not only substantially inhibited Akt activity, but also strongly suppressed HK2 expression in these cells (Fig. 3C). These results indicated that Akt, but not ERKs, was a key kinase of the EGCG-mediated downregulation of HK2.

**Constitutively activated Akt1 rescues EGCG-mediated glycolysis inhibition.** Based on the previous data, in order to confirm that the regulation of glycolysis by EGCG in human tongue carcinoma cells is dependent on Akt activity, we transfected constitutively activated Akt1 (Myr-Akt1) into Tca883 and TSCCa cells. The results indicated that 80 µM EGCG significantly decreased the expression of HK2 in Tca8113 and TSCCa cells. However, Myr-Akt1 transfection markedly upregulated HK2 expression in these EGCG-treated cells as expected (Fig. 4A and B, left). Moreover, Myr-Akt1 rescued over 70 and 60% of the deficient glucose uptake (Fig. 4A and B, middle) and lactate production (Fig. 4A and B, right) in EGCG-treated Tca8113 and TSCCa cells, respectively. These results suggested that EGCG regulates glycolysis in human tongue carcinoma cells, and these biochemical processes are partly mediated by Akt activation.

**EGCG inhibits HK2 expression on mitochondrial outer membrane and induces apoptosis.** The HK2 protein is crucial in cell proliferation as well as apoptosis resistance. In cancer cells, HK2 overexpression is associated with hyperactivated glycolysis and upregulated cell growth. More importantly, for HK2 to exert its anti-apoptotic function, HK2 translocates to the mitochondrial outer membrane and interacts with the voltage-dependent anion channel (VDAC) to block the release of cytochrome c, eventually inhibiting the apoptotic pathway (39-42). In order to assess the influence of EGCG on the subcellular localization of HK2, mitochondrial fractions from Tca8113 and TSCCa cells, with or without 80 µM EGCG treatment, were extracted and analyzed by immunoblotting with antibodies to detect HK2, α-tubulin and VDAC. The results indicated that the translocation of HK2 in the mitochondrial outer membrane fraction was decreased in the Tca8113 and TSCCa cells following EGCG treatment (Fig. 5A). Furthermore, we evaluated the apoptotic signaling pathway by immunoblotting to examine the cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase (PARP) expression after EGCG treatment. The results demonstrated that the levels of cleaved-caspase-3 and cleaved-PARP in Tca8113 and TSCCa cells were markedly increased in response to EGCG treatment (Fig. 5B). Based on these data, we suggested that the EGCG-mediated downregulation of HK2 inhibits anti-apoptotic effects of human tongue carcinoma cells.
Discussion

Oral cavity cancer is ranked as the sixth most widespread cancer type worldwide. Carcinoma of the oral tongue, the most common cancer in the oral cavity, exhibits invasion and/or metastasis at a very early stage. Surgery, radiotherapy, chemotherapy and combined modalities are the main treatment options for the tongue carcinoma (21-24). However, no molecular-targeted therapeutic drugs against tongue carcinoma are currently licensed, and the prevention strategies to decrease the incidence remain elusive. The limited therapeutic options provide a strong stimulus for the development of novel therapeutics. Preclinical studies have consolidated activity of EGCG in cancer prevention and, it was shown that inhibition of EGCG-induced proliferation and induction of apoptosis played an important role in its antitumor activity (5). However, how the underlying mechanisms of EGCG exert a tumor-suppressor effect through the metabolic pathways remains to be determined. We have demonstrated that EGCG had a profound antitumor activity in human tongue carcinoma cells in vitro. EGCG treatment decreased the expression of HK2 and inhibited its translocation into the mitochondrial outer membrane, while EGCG exerted its function in an Akt activity suppression-dependent manner.

In the present study, we first examined the antitumor activity of EGCG in two tongue carcinoma cells. The results indicated that EGCG markedly inhibited anchorage-independent growth of Tca8113 and TSCCa cells in a dose-dependent manner (Fig. 1A and B). These data are consistent with those of a previous study which reported that tea polyphenols have an inhibitory effect on the growth of oral squamous carcinoma cells (43). For cancer cells to sustain their rapid proliferation and gain a survival advantage, glycolysis has been demonstrated as a hot spot for metabolic reprogramming in tumor. This physiological process generates ATP for cell energy supply and provides sufficient biosynthetic intermediates for metabolic repurposing in tumor.
anabolic pathways (28). Although metabolic control over the glycolytic rate can be applied at many steps in the glycolytic pathway, most studies in cancer support the hypothesis that control over glycolytic flux primarily resides at the transport and phosphorylation steps (31). Findings of previous studies indicated that EGCG is associated with glucose uptake inhibition by regulating glucose transporter GLUTs, in different signaling pathways (44-47). Those findings suggested that EGCG may be involved in glycolysis regulation. Our results clearly showed that EGCG dose-dependently inhibited glucose consumption and lactate production in Tca8113 and TSCCa cells. Moreover, we found that EGCG directly decreased the expression of HK2 in these cells. These results suggest that EGCG regulates glycolysis in human tongue carcinoma cells.

HK2, the first rate-limiting enzyme in glycolysis, is considered to be required for tumor initiation and maintenance. Although the underlying mechanisms of the deregulation of HK2 in cancer cells have not yet been completely elucidated, the PI3-K/Akt-related signaling pathway, as well as the transcription factors, hypoxia inducible factors-1α (HIF-1α) and c-myc, have been demonstrated to be involved in the regulation of HK2 and HK2-mediated glycolysis (31). More importantly, overexpression of the receptor tyrosine kinase EGFR, accompanied by Akt hyperactivation is always observed in human tongue carcinoma and associated with tumor cell malignant properties (38,48). Thus, we hypothesized that the EGFR-Akt signaling pathway may regulate glycolysis in human tongue carcinoma. Our results show that EGCG substantially inhibited EGF-induced EGFR and its downstream kinase Akt and ERK phosphorylation as well as HK2 expression as expected. Subsequent analysis verified that the downregulation of HK2 in Tca8113 and TSCCa cells is mediated through the Akt signaling pathway, but is not dependent on ERK activity. In order to confirm our observations, a transient transfection of constitutively activated Akt1 (Myr-Akt1) was conducted in EGCG-treated human tongue carcinoma cells. Our results have demonstrated that Myr-Akt1 transfection promoted the expression of HK2 and rescued the glucose consumption and lactate production in Tca8113 and TSCCa cells, although in the presence of EGCG. These findings provide direct evidence that downregulation of Akt signaling pathway is involved in the suppression of EGCG-induced human tongue carcinoma glycolysis.

Findings of laboratory and clinical investigations have demonstrated that the high expression of HK2 is associated with resistance to cancer cell apoptosis (39,40). In this case, HK2 translocates to the mitochondrial outer membrane and interacts with the VDAC to block the release of cytochrome c, eventually inhibiting apoptosis (39-42). Our results indicate that EGCG obviously inhibited HK2 expression on the mitochondrial outer membrane and markedly promoted tongue carcinoma cell apoptosis. These results reveal a previously unknown mechanism of EGCG-induced tumor cell apoptosis, which may be partially dependent on HK2 subcellular localization. In summary, the present study suggests that glycolysis is involved in EGCG-mediated antitumor activity, and identified HK2 as a new potential target of EGCG. These results suggest that HK2 is a good molecular target for the prevention and treatment of human tongue carcinoma.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81371690), the International Cooperation Program Funds of the China Human Provincial Science and the Technology Department (project nos. 2012WK4005 and 2013FJ6009).

References


